TechAdvance® Fund Advances Rutgers Technologies Toward Commercialization with 22 Awards Totaling $1.45M

First Technology Funded by Program Licensed to Third Party

Created through Rutgers University’s Office of Research and Economic Development (ORED) to advance early stage technologies invented by Rutgers researchers toward commercialization, the TechAdvance® Fund has awarded $1.45 million to 22 researchers to date. Additionally, the first technology funded by the TechAdvance program has been successfully licensed to a third party.

Launched in June 2017, TechAdvance provides grants of up to $100,000 to Rutgers researchers whose inventions have the potential to become marketable products. Funded projects range from technologies in the life sciences and medical devices to materials science and engineering.

TechXpress, a program within TechAdvance, provides smaller grants of up to $10,000 for projects that require less funding and can be completed within six months. TechXpress funds may be used to create a prototype for a new device, purchase a compound for proof-of-concept studies, or fund a toxicology or efficacy experiment to increase the likelihood of patentability, for example.

Rutgers’ goal for this proof-of-concept fund is to bridge the gap between basic research and commercialization.

“Inventors often come to our office with hopes of marketing their new technologies to customers or industry partners. At the industry level, they often hear a common response that their technology is interesting but it’s too early or they need more data,” said David Kimball, Ph.D., Vice President for Innovation and Research Commercialization at Rutgers. “That’s where TechAdvance comes in. We provide funding with the goal of generating meaningful results that will increase the probability of follow-on funding, sponsored research, or commercialization through licensing, or the creation of a new startup. By giving these researchers the boost they need, we hope to bring more valuable Rutgers technologies to market and make a difference in the world around us.”

TechAdvance applications are evaluated by external industry reviewers to validate the market potential of each proposed technology and the goal is to support technologies that can be marketed via licensing to existing companies or the creation of new startups. All applications are accepted on a rolling basis, but applicants must be invited to apply. Information about the application process is available on the TechAdvance website.  

The TechAdvance program was established with $1 million of seed funding from ORED and continues to be supported by the university as well as donors, including alumni, foundations, industry partners, and members of the business community. 

Funded Projects to Date:

RESEARCHER

PROJECT TITLE

AWARD TYPE

David Shreiber Platform Technology for Native Free Radical-Initiated Targeting and Immobilization of Therapeutics TechAdvance

Bill Welsh

Sigma-1 Receptor (S1R) Antagonists as Alternatives to Opioid Narcotics for Treatment of Pain

TechXpress

Joachim Kohn

Targeted Delivery of Vitamin E acetate to skin using Rutgers TyroSpheres

TechAdvance

Biju Parekkadan

Biopharmaceutical Manufacturing using Bioactive Cell Growth Capsules

TechAdvance

Arash Hatefi

Vector Development for Stem Cell Transfection

TechXpress

Thomas Papathomas

Diagnostic Application for Schizophrenia and mental disorders

TechAdvance

Rafael Benoliel

Biomimetic, Bioactive Dental Implants

TechAdvance

Chaoyang Xue

Development of a broad-spectrum antifungal vaccine

TechAdvance

Masanori Hara

Scale-up and Mechanical Testing of Polymers made from Silica

TechXpress

Fumio Matsumura

In vitro generation of antigen-specific memory T-cells

TechXpress

Gary Aston Jones

A novel composition and method for treating neuropsychiatric disorders

TechAdvance

Manisha Bajpai

Clinical Validation of FISH Based Assay for Early Detection of Esophageal Adenocarcinoma

TechAdvance

Richard Ebright

New Antibiotics: Microbial Extract Screening and Mutational De-Replication

TechAdvance

Ed Yurkow

Treatment of Fibrotic Diseases Using Agents that Disrupt the Structure of Collagen

TechXpress

Bill Belden

Synthetic Antibody Production for Immunotherapies

TechXpress

Judy Deutsch

VSTEP digital health platform using virtual environments (VE) for examination and rehabilitation of balance, coordination, mobility and fitness

TechAdvance

G. Charles Dismukes

Waste Carbon Dioxide into Renewable Chemical Feedstocks and Energy Storage via Electro-catalysis

TechAdvance

Joseph Freeman

Vascularized Regenerative Scaffold for Load Bearing Bone

TechXpress

Yicheng Lu

MZO Nanostructure-Modified Bulk Acoustic Wave Biosensor for Dynamic and Rapid Determination of Antimicrobial Efficacy and Resistance

TechAdvance

Jennifer Lynch

Graphene Enhanced Polymer Matrix Composites: Investigation of the Barrier Resistance to Small Gases and Fuel

TechAdvance

Prabhas Moghe

Optical Surveillance for Drug Discovery & Disease Tracking: “Ink and Scan” Infrared Nanotechnology

TechAdvance

Bill Welsh

First-in-Class Pan-TAM Tyrosine Kinase Inhibitors for Cancer Therapy

TechAdvance